Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer Sues Johnson & Johnson Over Claim That Prostate Cancer Drug Cuts Risk Of Death

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Doc Murdered 8 Patients? RFK Jr. Will 'Cost Lives'; $412M in Penile Injection Case

Health news and commentary gathered by MedPage Today staff

Todays Updates

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

LAAC an Alternative for NOAC in Lower-Risk AF Patients

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Fibrinolytic Beats Current Standard for Intermediate-Risk PE

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

High Dx Yield Supports Workup for INOCA

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Todays Updates

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

LAAC an Alternative for NOAC in Lower-Risk AF Patients

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Fibrinolytic Beats Current Standard for Intermediate-Risk PE

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

High Dx Yield Supports Workup for INOCA

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Latest News

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Health news and commentary gathered by MedPage Today staff

News All Time

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

In infants, laparoscopic robotic pyeloplasty is safe and has a success rate comparable to open surgery.

The results of minimally invasive pyeloplasty (MIP) for the primary cause, ureteropelvic junction obstruction (UPJO), were examined in a recent study.

Medical Bulletin November 30, 2023.

The top medical stories of the day are as follows: ADHD increases the risk of car crashes in older adults. ADHD is a neurodevelopmental disorder that is chronic and has symptoms.

Recommended News For You

An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.

AI innovation unlocks non-surgical way to detect brain cancer spread

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type

Recommended Articles For You

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies 

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide 

Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights 

Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Novel Agent for Chronic GVHD Wins FDA Approval

2.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

3.

Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.

4.

New research demonstrates a method for screening people at high risk for pancreatic cancer.

5.

'Converging' Evidence of Link Between Air Pollution and Breast Cancer

1.

Lu-177 Vipivotide in Prostate Cancer: A Breakthrough in Radioligand Therapy

2.

Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs

3.

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies

4.

HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians

5.

The benefits and risks of taking fludrocortisone for adrenal insufficiency 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

2.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

4.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

5.

Efficient Management of First line ALK-rearranged NSCLC - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot